Please provide your email address to receive an email when new articles are posted on . Children with eosinophilic esophagitis currently rely on elimination diets. The safety profile for this age ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved dupilumab for eosinophilic esophagitis in children in January. Patients achieved improvements ...

NEW ORLEANS, La. (Ivanhoe Newswire)-- We’ve all seen them and some of us have one at home: picky eaters. A toddler that just won’t eat, no matter what you put on their plate. Well, it may be just a ...

Researchers evaluated the potential predictive characteristics of eosinophilic esophagitis following IBD diagnosis in children. Children with inflammatory bowel disease (IBD) appear to have an ...

Eosinophilic Esophagitis (EoE): it's probably the most common allergic reaction you've never heard of. It's a condition that causes the tissues of the esophagus (the tube that connects the mouth to ...

The US Food and Drug Administration (FDA) has approved dupilumab (Dupixent, Regeneron/Sanofi) for the treatment of eosinophilic esophagitis (EoE) in children aged 1-11 years and weighing ≥ 15 kg. It ...

Approval based on phase 3 data showing significantly more children aged one to 11 years on Dupixent achieved histological disease remission at 16 weeks compared to placebo, which was sustained up to ...

If approved, the treatment would be the first of its kind for young children enduring eosinophilic esophagitis (EoE). A supplemental Biologics License Application (sBLA) for dupilumab (Dupixent) for ...

A recent study attempted to determine the prevalence of eosinophilic esophagitis (EoE) in a group of patients allergic to milk or egg and undergoing oral immunotherapy (OIT) to those foods, as well as ...

Share on Pinterest The condition eosinophilic esophagitis can make it difficult for children to eat. Westend61/Getty Images Researchers have published new research about eosinophilic esophagitis (EoE) ...

TARRYTOWN, N.Y. and PARIS, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Medicines Agency’s Committee for Medicinal ...

Dupilumab, a fully human monoclonal antibody, blocks interleukin-4 and interleukin-13 signaling, which have key roles in eosinophilic esophagitis. We conducted a three-part, phase 3 trial in which ...